In Brief: Roche
Roche: Petitions FTC to drop preclearance provisions included in consent agreements related to 1990 acquisition of a controlling interest in Genentech and 1994 buy-out of Syntex. Under terms of the two agreements, Roche must preclear any acquisition of an interest in vitamin C, human growth factor or CD4-based therapeutics or any drug abuse testing lab. The petition responds to an FTC policy adopted in June, under which the commission determined not to seek preclearance in most cases and instead rely on existing Hart-Scott-Rodino notification procedures...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth